Spots Global Cancer Trial Database for Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients

Official Title: A Randomized Phase II Study of Lenalidomide Maintenance Therapy in AML Patients Aged > 60 Years in CR1 or Higher and < 60 Years in CR2 or Higher

Study ID: NCT00957385

Conditions

Acute Myeloid Leukemia

Interventions

Revlimid

Study Description

Brief Summary: The purpose of this study is to determine if Revlimid will help maintain patients with acute myeloid leukemia in remission.

Detailed Description: At present, the majority of AML patients \>60 years of age that achieve CR and thereafter successfully complete further chemotherapy, are not candidates for allogeneic bone marrow transplantation (alloBMT) due to their age. Rather, this group of patients is simply observed until relapse occurs. In this age group, the median duration of CR is only \~10 months. The survival of patients \<60 years of age who are not candidates for transplantation (due to donor unavailability), and who are in CR2 or higher is also extremely poor. Several lines of evidence suggest that the immune system - and in particular AML specific CTLs and NK cells - is capable of recognizing and clearing AML cells.